8/102 sources · 2 publishersUpdated Oct 29, 02:47 UTC
NeoGenomics raises 2026 revenue outlook and announces CEO transition
NeoGenomics Inc. reported third‑quarter 2026 revenue of $209 million, a 11% year‑over‑year increase, and adjusted EBITDA of $19 million, up 53% YoY. Clinical revenue grew 13% YoY and NGS revenue rose 29% YoY, driving margin expansion of more than 300 basis points. The company lifted its full‑year 2026 revenue guidance to $807 million‑$809 million and said Warren Stone will become CEO on 4 January 2027, with Tony Zook moving to Executive Chairman.
Why it matters
The company expects the higher revenue range to improve earnings outlook for 2026, and the leadership change is intended to ensure strategic continuity into 2027.
Key facts
- 1Total revenue for Q3 2026 was $209 million, an 11% YoY increase. investing.com
- 2Adjusted EBITDA for Q3 2026 was $19 million, a 53% YoY increase. investing.com
- 3Clinical revenue grew 13% YoY to $195 million. investing.com
- 4NGS revenue grew 29% YoY. investing.com
- 5Adjusted gross margin expanded by more than 300 basis points year‑over‑year. investing.com
- 6Full‑year 2026 revenue guidance was raised to $807 million‑$809 million. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.